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Abstract
Cardiovascular diseases are prevalent in patients with chronic obstructive pulmonary disease (COPD). Their
coexistence implies that many COPD patients require anticoagulation therapy. Although more and more replaced
by direct oral anticoagulants, vitamin K antagonists (VKAs) are still widely used. VKAs induce profound deficiency of
vitamin K, a key activator in the coagulation pathway. It is recognized however that vitamin K is also an essential
cofactor in the activation of other extrahepatic proteins, such as matrix Gla protein (MGP), a potent inhibitor of
arterial calcification. No or insufficient MGP activation by the use of VKAs is associated with a rapid progression of
vascular calcification, which may enhance the risk for overt cardiovascular disease. Vitamin K consumption, on the
other hand, seems to have a protective effect on the mineralization of arteries. Furthermore, vascular calcification
mutually relates to elastin degradation, which is accelerated in patients with COPD associating with impaired
survival. In this commentary, we hypothesize that vitamin K is a critical determinant to the rate of elastin
degradation. We speculate on the potential link between poor vitamin K status and crucial mechanisms of COPD
pathogenesis and raise concerns about the use of VKAs in patients with this disease. Future intervention studies are
needed to explore if vitamin K supplementation is able to reduce elastin degradation and vascular calcification in
COPD patients.
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Background
Cardiovascular diseases are more prevalent in patients
with chronic obstructive pulmonary disease (COPD)
compared to age- and smoking-matched controls with
no lung disease [1]. Vascular calcification is a major risk
factor for cardiovascular morbidity and mortality. COPD
patients have on average more extensive coronary artery
calcification (CAC) than controls [2]. Furthermore, the
burden of emphysema is related to the thoracic aortic
calcification score [3]. The frequency of cardiac arrhyth-
mias is also high in patients with COPD [1], and an
inverse association has been identified between forced
expiratory volume in one second and incident atrial fib-
rillation [4]. Atrial fibrillation and pulmonary embolism
may be both cause and consequence of acute COPD ex-
acerbations, and often necessitate prolonged anticoagu-
lation therapy [5, 6].
Although the use of direct oral anticoagulants
(DOACs) is rising, vitamin K antagonists (VKAs) are
still widely used as anticoagulant drugs. VKAs inhibit
vitamin K recycling thereby inducing functional vitamin
K deficiency [7, 8]. Vitamin K is generally known as an
activator of coagulation proteins in the liver and there-
fore often incorrectly regarded as a mono-functional
cofactor [9]. It is much less acknowledged that vitamin
K is also essential in the activation of extrahepatic key-
proteins [9]. Matrix Gla protein (MGP) is vitamin
K-dependent and a potent inhibitor of soft tissue calcifi-
cation [10]. Furthermore, evidence suggests a potential
role for MGP in the protection of extracellular matrix
proteins from enzymatic degradation [11]. MGP knock-
out mice die within two months after birth due to
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vascular calcifications leading to large blood vessel rup-
ture, illustrating the importance of MGP [10]. Although
research has mainly focused on its protective effects
against arterial pathologies [12], MGP is also extensively
expressed in the lungs [13].
Vitamin K status
Vitamin K cannot be produced endogenously and is
exclusively obtained exogenously. Different forms of
vitamin K can be discerned, including naturally occur-
ring vitamins K1 and K2 [14]. Vitamin K2 usually com-
prises not more than about one-tenth of total vitamin K
consumption, but it holds a much larger share in the ac-
tivation of vitamin K-dependent proteins as vitamin K2
has higher bioavailability and longer half-life time than
K1 [14]. Although there is no absolute tissue specificity,
vitamin K1 is preferentially used in the liver to activate
coagulation factors, whereas vitamin K2 has a more
prominent role in the activation of extrahepatic vitamin
K-dependent proteins, such as MGP [15].
Vitamin K1 levels can be reliably measured in the
circulation and reflect the intake of vitamin K1 [16].
Vitamin K2, however, usually cannot be detected in the
blood stream unless taken as supplements [16]. To date,
there is no gold standard for assessing total vitamin K
status, although measuring inactive levels of vitamin
K-dependent proteins in the circulation seems to be the
most appropriate method [16]. Desphospho-uncarboxylated
(dp-uc; i.e. inactive) MGP levels are often used as a surrogate
marker for vitamin K status. Dp-ucMGP levels are inversely
correlated with vitamin K status, which means that subjects
with high dp-ucMGP levels have low vitamin K status and
vice versa [16].
There are several potential reasons why vitamin K sta-
tus might be impaired (Fig. 1). Obviously, it can be the
result of low vitamin K consumption. Cheese is an im-
portant source of vitamin K2 in many countries. In rela-
tion to COPD, it is interesting that cheese consumption
was shown to be associated with better lung function
and less emphysema in a large observational study [17].
Differences in vitamin K metabolism due to the use of
VKAs or genetic variation are other causes of a lower
vitamin K status. The human body uses vitamin K very
economically given that it is reused about 2000 fold via
the so-called vitamin K cycle (Fig. 2). The two reduction
steps of this cycle are executed by the enzyme vitamin
K epoxide reductase (VKOR). VKAs are specific inhibi-
tors of VKOR [7], which is the explanation for the poor
vitamin K status found in subjects using these anti-
coagulant drugs [8]. The VKOR activity is also influ-
enced by single nucleotide polymorphisms (SNPs) in the
VKOR complex subunit 1 (VKORC1) gene, which are in
linkage disequilibrium with each other [7]. VKORC1
SNPs that are associated with low vitamin K recycling
rates may be overrepresented in subjects with low vitamin
K status. The T-allele of the VKORC1 1173C > T SNP as-
sociates with poor vitamin K recycling and a significantly
higher risk of aortic calcification [18]. We could further
speculate that the VKORC1 C1173T SNP might also influ-
ence the susceptibility to COPD or specific phenotypes
such as emphysema. Genetic association studies are
needed to assess whether this hypothesis holds true
Finally, it is possible that subjects with enhanced rates
of elastin degradation have higher vitamin K expenditure
given that elastin degradation stimulates elastin calcifica-
tion [19]. A rising calcium content in elastin fibers stim-
ulates MGP synthesis in an attempt to prevent further
calcium precipitation within the elastin fibers [20]. How-
ever, MGP first needs to be activated by vitamin K. This
increased vitamin K demand might induce a vitamin K
deficit.
Fig. 1 Proposed mechanisms that could be responsible for vitamin K
deficiency. Low vitamin K consumption and use of vitamin K antagonists
induce vitamin K deficiency. It is likely that polymorphisms in vitamin
K epoxide reductase complex subunit 1 (VKORC1) gene associated with
low vitamin K recycling rates predispose to vitamin K deficiency.
Accelerated elastin degradation, due to a protease/antiprotease
imbalance, leads to elastin calcification and subsequently to an increased
synthesis of matrix Gla protein, which needs to be activated by vitamin K.
This increased vitamin K demand might also cause a vitamin K deficit
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Elastin calcification and degradation
Vascular calcification usually starts in the elastin fi-
bers of the arterial medial wall [19]. Elastin is a
unique protein that provides elasticity, resilience and
deformability to dynamic tissues, such as arteries and
lungs [21]. It is mainly produced in utero and early
childhood after which elastin synthesis is suppressed
at a posttranscriptional level [21]. During the aging
process, the elastic properties of elastin fibers can be
compromised by both calcification and degradation
[21]. Elastin has high affinity for calcium, and as a re-
sult its calcium content increases during aging [22].
Arterial calcifications can be induced in rats via the
administration of VKAs to induce vitamin K defi-
ciency and thereby preventing vitamin K-dependent
MGP activation [11]. A similar mechanism has also
been demonstrated in humans in whom the use of
VKAs is associated with more vascular calcifications
[23, 24]. This is of course highly undesirable in
calcification-prone COPD patients.
Elastin degradation is enhanced in patients with
COPD due to an imbalance between the protective
effects of antiproteases and the destructive properties of
proteases. In COPD patients, elastinolysis is not only
accelerated in lungs but also in other elastin-rich tissues
[25]. The severity of emphysema is correlated with arter-
ial stiffness and skin wrinkling, indicating that a process
of “systemic elastin degradation” may occur in COPD
[25]. Desmosine and isodesmosine (DES) are two amino
acids that are only present in crosslinked elastin fibers,
and plasma DES levels therefore reflect the rate of elas-
tin degradation. The COPD Biomarker Qualification
Consortium regards DES as biomarkers with great
potential [26]. In a uniform cohort of COPD patients
with alpha-1 antitrypsin (AAT) deficiency, plasma DES
was related to emphysema progression [27]. Plasma DES
levels were not associated with emphysema in a cohort
of patients with a variety of COPD endotypes and phe-
notypes [28]. However, they were correlated with arterial
stiffness and cardiovascular comorbidity in these hetero-
geneous COPD patients [28], which probably indicates
that the vascular compartment is the main contributor
of elastin degradation products in the blood stream of
most AAT sufficient COPD patients. Remarkably, plasma
DES levels were also associated with the CAC score,
illustrating the close relationship between elastinolysis
and vascular calcification [28].
Elastin calcification and degradation are two pathogenic
mechanisms that stimulate each other [19]. Administration
of calcium chloride (CaCl2) in rat aortas induced both elas-
tin calcification and degradation [19]. Inhibiting elastin
degradation, prior to CaCl2 administration, also reduced
elastin calcification [19]. The calcification promoting ac-
tions of elastases are probably based on the higher affinity
of degraded elastin for calcium than intact elastin probably
due to increased polarity of the former [22]. Elastin calcifi-
cation, on the other hand, induces an upregulation of
matrix metalloproteinase (MMP) gene expression leading
to an acceleration of elastin degradation [29]. In an animal
model, it has been demonstrated that VKAs not only
induced elastin mineralization but also promoted elastin
degradation [11]. MMP-9 activity even preceded macro-
scopic elastin calcification [11]. The interrelationships be-
tween elastin calcification, elastin degradation and the
actions of MGP could potentially be a pathomechanistic
explanation for the observed link between COPD and car-
diovascular diseases.
Osteoporosis and vascular calcification
Remarkably, demineralization of bone tissue and
mineralization of arteries often coexist in individual
patients with COPD [30, 31]. The mechanism behind
this apparently paradoxical link has yet to be established.
We speculate that insufficient activation of the vitamin
Fig. 2 Vitamin K cycle. Food-derived vitamin K first needs to be converted
into the active metabolite vitamin K hydroquinone (KH2). During the
activation process of vitamin K-dependent proteins, the cofactor KH2 is
converted into vitamin K epoxide (KO). Subsequently, inactive KO has to
be reduced, first into vitamin K and then into KH2. These two reduction
steps are executed by the enzyme vitamin K epoxide reductase (VKOR).
VKAs are specific inhibitors of VKOR
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K-dependent proteins osteocalcin (OCN) and MGP
might be involved. Whereas activated OCN is regarded
as a regulator of mineralization in bone tissue, MGP
protects extra-osseous tissues from calcification. This
concept is supported by a randomized-controlled trial in
postmenopausal women demonstrating that vitamin K2
supplementation ameliorated both bone loss and arterial
stiffening [32, 33]. Future studies in well-characterized
cohorts have to reveal whether vitamin K deficiency is
indeed the linking pin between osteoporosis and vascu-
lar calcifications in COPD.
Vitamin K supplementation
Preliminary data of our group suggest that vitamin K
status is reduced in patients with COPD compared to
controls [34]. We also found an inverse association
between vitamin K status and plasma DES levels; i.e.
lower vitamin K status related to accelerated elastin deg-
radation [34].
The rate of elastin degradation seems to be a strong
independent predictor of mortality in COPD [28].
Decelerating elastin degradation might therefore be an
attractive therapeutic target in COPD. A recent trial, in
which AAT augmentation therapy reduced plasma DES
levels in COPD patients with AAT deficiency, serves as
a convincing proof-of-principle for this intriguing con-
cept [27]. Since vitamin K supplementation can be
hypothesized as an alternative therapeutic strategy, an
intervention trial should be conducted to assess whether
vitamin K supplementation does indeed decelerate elas-
tin degradation in patients with COPD.
Vitamin K has an excellent safety profile, and no tox-
icity has been observed even with very high-doses [35].
Vitamin K is obligatory to maturate clotting factors in
the liver, however, it is also necessary for the activation
of anticlotting factors (i.e. protein C and S). Whereas
protein C is solely produced in the liver, about 50% of
protein S is synthesized hepatically and the other half in
the vascular wall [36]. Protein S production in the vascu-
lar system seems to be of key importance in local throm-
bosis prevention [36]. The triage theory posits that in
case of scarcity, nature will provide nutrients first to
places in the body where shortage leads to an immediate
treat to short-term survival at the expense of places
where shortage only has long-term consequences (Fig. 3)
[37]. Regarding vitamin K deficiency, increased bleeding
tendency is the biggest short-term threat for survival,
and the limited supply of vitamin K will therefore be
preferentially used for the synthesis of clotting factors
with the sacrifice of protein S maturation in the vascular
wall [37]. Therefore, counterintuitively, vitamin K sup-
plementation does not increase the risk of thrombo-
embolism and might even decrease it by fully activating
the anti-thrombosis activity [37]. The triage theory also
implies that MGP activation in VKA-users is more
severely compromised than the activation of coagulation
factors [38], which might have deleterious effects on vas-
cular calcifications, elastin degradation and survival in
patients with COPD.
Vitamin K1 and K2 in cardiovascular diseases
Whether vitamin K2 alone or both vitamin K1 and K2
have beneficial effects on vascular calcification remains
partially elusive. Data from observational studies suggest
that vitamin K2 rather than vitamin K1 has protective
properties against cardiovascular morbidity and mortal-
ity [39, 40]. Participants in the non-interventional
Rotterdam study were categorized based on the esti-
mated consumption of vitamin K1 and K2 [39]. Subjects
from the upper vitamin K2 intake tertile had 0.57 lower
relative risk of cardiovascular mortality than those from
the lowest one [39]. The presence of severe aortic calcifi-
cation in the highest tertile for vitamin K2 intake was
also less than 50% compared to that in the lowest tertile
[39]. Vitamin K1 was not related to either mortality or
aortic calcification in the Rotterdam study [39]. The sugges-
tion of a protective effect of vitamin K2 consumption and
an indifferent effect of vitamin K1 on vascular calcification
was corroborated in the observational Prospect-EPIC study
[40]. More than 16,000 women were followed for on aver-
age 8 years, and, unlike higher vitamin K1 intake, higher
Fig. 3 Triage theory. The triage theory implies that in case of mild
vitamin K deficiency the coagulation factors are still activated by
vitamin K, however, the anticoagulation protein S in the vascular
wall and matrix Gla protein are insufficiently activated. This will lead
to both increased thrombosis risk and elastin calcification. Elastin
calcification causes elastin degradation and vice versa. Elastin
degradation in the lungs leads to lung emphysema. Vascular
calcification begins at the elastin fibers in the vascular walls. Only in
case of severe vitamin K deficiency, coagulation factors are also
insufficiently activated leading to increased bleeding tendency
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intake of vitamin K2 was associated with reduced incidence
of coronary heart disease [40].
Intervention trials, on the other hand, suggest a favor-
able effect of both vitamin K1 and K2 on cardiovascular
pathology. A randomized-controlled trial assessed the
effect of one year vitamin K1 supplementation on aortic
valve calcification, which turned out to progress signifi-
cantly slower in the active arm [41]. In another interven-
tional trial, postmenopausal women were supplemented
with vitamin K2 or placebo for three years [32]. Vitamin
K2 improved arterial compliance, especially in those
women with high stiffness at baseline [32]. Arterial stiff-
ness is a strong independent predictor of cardiovascular
risk [42], which is for a large part caused by the patho-
physiological processes elastinolysis and elastocalcinosis
[19]. COPD patients have increased stiffening of their
arteries compared to controls [43]. Whether vitamin K
supplementation has favorable effects on arterial stiff-
ness in COPD is currently unknown. Future studies are
needed to assess whether vitamin K could help to pre-
vent cardiovascular diseases in patients with COPD.
In a rat model, equivalent doses of vitamin K1 and K2
were equally effective in reversing vascular calcifications
[44]. Inactivation of MGP by the administration of VKAs
led to rapid calcification of arteries in these animals [44].
Subsequently, both high-dose vitamin K1 and K2 supple-
mentation reduced the calcium content in the rats’ arter-
ies by some 50% [44].
It might be that the differences between the effects of
vitamin K1 and K2 supplementation are dose-dependent.
Given the lower vitamin K1 bioavailability and shorter
half-life compared to that of K2, it is conceivable that
higher doses of vitamin K1 are needed to achieve the same
results on cardiovascular endpoints than with vitamin K2.
Effect of vitamin K antagonists on elastin degradation
Since the rate of elastinolysis is related to mortality in
COPD [28], we speculate that the stimulating effect of
VKAs on elastin degradation might contribute to disease
progression and mortality in patients with COPD. VKAs
cause vitamin K deficiency leading to inadequate levels
of active MGP to protect elastin fibers from calcification.
MGP is virtually the only protein that is able to inhibit
elastin calcification given other anti-calcifying proteins,
such as fetuin, are too large to penetrate into the interior
of the elastin fibers [12, 45]. Microscopic elastin calcifi-
cation induces an increase of MMP synthesis leading to
accelerated elastin degradation [29]. Preliminary data of
our group suggest that VKAs have an accelerating effect
on elastin degradation [46]. Plasma DES levels were
higher in VKA-users compared to subjects not using
these anticoagulant drugs [46]. However, additional stud-
ies are still required to unequivocally establish that
VKAs enhance elastin breakdown.
Alternative anticoagulant drugs in COPD
The use of VKAs has reduced in recent years following
the introduction of DOACs. Contrary to VKAs, DOACs
work directly on coagulation factors thrombin or factor
Xa without interrupting the vitamin K cycle and the
activation of MGP. It is therefore not to be expected that
DOACs promote vascular calcification and/or elastin
degradation. A variety of studies are currently registered
on ClinicalTrials.gov comparing the effects of VKAs and
DOACs on progression of vascular calcification [47].
Our group intends to conduct a trial assessing the differ-
ential effects of both anticoagulant drugs on elastolysis.
These clinical studies are needed to unequivocally estab-
lish the effects of VKAs and DOACs on central mecha-
nisms of COPD pathogenesis. With the current state of
scientific evidence, however, it might already be argued
that VKAs are better to be avoided in COPD patients
given the established adverse effect of VKAs on arterial
mineralization and the high prevalence of cardiovascular
diseases in COPD [1, 23, 24].
Future studies assessing the role of vitamin K in COPD
pathogenesis
Additional animal and human studies are needed to fully
unravel the role of vitamin K on the development and
progression of COPD.
A variant of the smoking mouse model, previously ap-
plied to study the effects of vitamin D status on emphy-
sema formation [48], could be used to assess the effects
of high and low vitamin K status on lung destruction.
Analogously to a rat model of vascular calcification, vita-
min K deficiency is probably best induced in these ex-
periments by combining high-dose VKAs to prevent
vitamin K-dependent MGP activation with vitamin K1 to
prevent hemorrhage [11].
Furthermore, large human cohort studies are needed
to see if vitamin K deficiency is a significant factor for
pulmonary disease progression in COPD. Intervention
trials in patients with COPD are necessary to assess
whether vitamin K administration may decelerate pul-
monary elastin degradation and emphysema progression.
Conclusions
Abundant circumstantial evidence, both from human
observational studies and from animal intervention stud-
ies, points to a link between low vitamin K levels, elastin
degradation and cardiovascular pathology in COPD
patients. As VKAs are still widely used in this particular
population concerns may rise on their long-term safety
profile. Vitamin K intervention studies are warranted to
reveal if vitamin K supplementation may play a role in
the management of patients with COPD.
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